PMID- 10037371
OWN - NLM
STAT- MEDLINE
DCOM- 19990318
LR  - 20190621
IS  - 0022-5347 (Print)
IS  - 0022-5347 (Linking)
VI  - 161
IP  - 1
DP  - 1999 Jan
TI  - Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin 
      treatment: can it predict the optimal number of instillations?
PG  - 67-71
AB  - PURPOSE: In patients with superficial bladder cancer treated with a first 6-week 
      instillation course of bacillus Calmette-Guerin (BCG) the induction pattern of 
      urinary interleukin (IL)-2 has been described, and the levels of urinary IL-2 
      were associated with the clinical response to BCG treatment. We evaluated urinary 
      IL-2 kinetics in patients with recurrent superficial bladder tumor receiving a 
      second or third 6-week BCG instillation course. To our knowledge there have been 
      no studies of prolonged BCG treatment and urinary cytokine responses. MATERIALS 
      AND METHODS: Urinary IL-2 was determined in 12 patients with superficial 
      transitional cell carcinoma of the bladder receiving a complete (6-week) second 
      or third BCG instillation course and in 3 patients receiving 3 BCG instillations 
      during a maintenance schedule at month 3. Urinary IL-2 was determined with an 
      enzyme-linked immunosorbent assay using an oligoclonal system. RESULTS: Of 12 
      patients 10 had a urinary IL-2 positive response during the subsequent BCG course 
      and at week 1 urinary IL-2 was already increased. Comparing the urinary IL-2 
      kinetics observed during a second or third with a first course, urinary IL-2 
      tended to be higher during the first and lower during the last weeks. If the 
      interval between subsequent courses was short (12 months or less) significantly 
      higher urinary IL-2 levels at weeks 1 and 2, and a lower level at week 6 were 
      observed. CONCLUSIONS: During a repeat BCG instillation course urinary IL-2 
      reached a maximum at an earlier week, especially if the interval between the 
      subsequent courses was short. Since an association between urinary IL-2 levels 
      and response to BCG treatment during an induction course has been observed, these 
      immunological data argue in favor of a limited number of instillations during 
      prolonged BCG therapy which could reduce side effects as well as costs.
FAU - de Reijke, T M
AU  - de Reijke TM
AD  - Department of Urology, University of Amsterdam, The Netherlands.
FAU - De Boer, E C
AU  - De Boer EC
FAU - Kurth, K H
AU  - Kurth KH
FAU - Schamhart, D H
AU  - Schamhart DH
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (BCG Vaccine)
RN  - 0 (Interleukin-2)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Administration, Intravesical
MH  - BCG Vaccine/*administration & dosage
MH  - Carcinoma, Transitional Cell/*therapy/*urine
MH  - Humans
MH  - Interleukin-2/*urine
MH  - Monitoring, Physiologic
MH  - Neoplasm Recurrence, Local/*therapy/*urine
MH  - Predictive Value of Tests
MH  - Time Factors
MH  - Urinary Bladder Neoplasms/*therapy/*urine
EDAT- 1999/02/26 00:00
MHDA- 1999/02/26 00:01
CRDT- 1999/02/26 00:00
PHST- 1999/02/26 00:00 [pubmed]
PHST- 1999/02/26 00:01 [medline]
PHST- 1999/02/26 00:00 [entrez]
AID - S0022-5347(01)62065-2 [pii]
AID - 10.1097/00005392-199901000-00024 [doi]
PST - ppublish
SO  - J Urol. 1999 Jan;161(1):67-71. doi: 10.1097/00005392-199901000-00024.